Inhibition of telomerase activity as a strategy to target the cancer stem cell population in lung and breast tumours

• Autores: Diego Serrano Tejero
• Directores de la Tesis: Alfonso Calvo González (dir. tes.), Anne-Marie Bleau (codir. tes.)
• Lectura: En la Universidad de Navarra ( España ) en 2011
• Idioma: español
• Tribunal Calificador de la Tesis: Carlos Ortiz de Solórzano Aurusa (presid.), Estanislao Nistal Villán (secret.), Robert Clarke (voc.), M. Carmen Ramirez Castillejo (voc.), Julián Carretero Asunción (voc.)
• Materias:
  • Ciencias de la vida
    • Biología celular
  • Ciencias médicas
    • Ciencias clínicas
      • Oncología
    • Patología
      • Carcinogénesis
      • Oncología
• Texto completo no disponible (Saber más ...)
• Resumen

  • Mortality rates for advanced lung and breast cancer have not declined for decades, even with the implementation of novel chemotherapeutic regimens or the use of tyrosine kinase inhibitors. Cancer Stem Cells (CSCs) are thought to be responsible for resistance to chemo/radiotherapy. Therefore, targeting CSCs with novel compounds may be an effective approach to reduce tumor growth and metastasis. We have isolated and characterized CSCs from non-small cell lung cancer (NSCLC) cell lines and measured their telomerase activity, telomere length, and sensitivity to the novel telomerase inhibitor MST312.

    The aldehyde dehydrogenase (ALDH) positive lung cancer cell fraction is enriched in markers of stemness and endowed with stem cell properties. ALDH+ CSCs display longer telomeres than the non-CSC population. Interestingly, MST312 has a strong antiproliferative effect on lung and breast CSCs and induces p21, p27 and apoptosis in the whole tumor population. MST312 acts through activation of the ATM/pH2AX DNA damage pathway (short-term effect) and through decrease in telomere length (long-term effect). Administration of this telomerase inhibitor (40 mg/kg) in the H460 xenograft model results in significant tumor shrinkage (70% reduction, compared to controls). Combination therapy consisting of irradiation (10Gy) plus administration of MST312 did not improve the therapeutic efficacy of the telomerase inhibitor alone. Treatment with MST312 reduces significantly the number of ALDH+ CSCs and their telomeric length in vivo.

    We conclude that antitelomeric therapy using MST312 mainly targets lung and breast CSCs and may represent a novel approach for effective treatment of cancer.